{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-129431","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.799613+00:00","generated_at":"2026-05-15T08:39:34.613364+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Q32 Bio enters ATM sales agreement for up to $14.2M common stock offering","bullets":["Enters Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. for at-the-market sales.","May sell shares with aggregate offering price up to $14.2 million via prospectus supplement filed March 27, 2026.","Sales made on Nasdaq or other trading markets; Agent receives 3.0% cash commission on gross proceeds.","Company not obligated to sell any shares; can suspend or terminate offering on notice to Agent.","Uses existing shelf registration statement Form S-3 (File No. 333-286491) effective April 21, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-129431","json":"https://secwatch.observer/filing/0001193125-26-129431.json","markdown":"https://secwatch.observer/filing/0001193125-26-129431.md","text":"https://secwatch.observer/filing/0001193125-26-129431.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526129431/0001193125-26-129431-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526129431/d12934d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:39:34.613364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ab6ecd1b7f45cedf425ca28083963f6c461c268","claim":"Q32 Bio Inc. entered into Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. valued at up to $14,200,000 (effective 2026-03-27).","evidence_excerpt":"On March 27, 2026, Q32 Bio Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Sales Agent”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526129431/0001193125-26-129431-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co."},{"label":"Value","value":"up to $14,200,000"},{"label":"Effective","value":"2026-03-27"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}